Across TCGA pan-cancer cohorts, OR5AC2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR5AC2 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OR5AC2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OR5AC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, BRCA, and LIHC are the cancer types where OR5AC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.622	.022	10	view →
BRCA	DFS	Median	All	0.152	0.526	.034	8	view →
LIHC	OS	Median	All	0.047	0.783	<.001	6	view →
COAD	OS	Median	IV	0.140	0.657	.035	3	view →
HNSC	OS	Median	All	0.578	0.710	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: OR5AC2 tumor-vs-normal RNA expression · all OR5AC2 data types